PAZOPANIB Drug Patent Profile
✉ Email this page to a colleague
When do Pazopanib patents expire, and when can generic versions of Pazopanib launch?
Pazopanib is a drug marketed by Apotex, Eugia Pharma, Novugen, Sun Pharm, Teva Pharms Inc, and Torrent. and is included in six NDAs.
The generic ingredient in PAZOPANIB is pazopanib hydrochloride. There are five drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the pazopanib hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pazopanib
A generic version of PAZOPANIB was approved as pazopanib hydrochloride by APOTEX on October 19th, 2023.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PAZOPANIB?
- What are the global sales for PAZOPANIB?
- What is Average Wholesale Price for PAZOPANIB?
Summary for PAZOPANIB
| US Patents: | 0 |
| Applicants: | 6 |
| NDAs: | 6 |
| Drug Prices: | Drug price information for PAZOPANIB |
| DailyMed Link: | PAZOPANIB at DailyMed |
US Patents and Regulatory Information for PAZOPANIB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apotex | PAZOPANIB HYDROCHLORIDE | pazopanib hydrochloride | TABLET;ORAL | 217713-001 | Oct 19, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Sun Pharm | PAZOPANIB HYDROCHLORIDE | pazopanib hydrochloride | TABLET;ORAL | 215837-001 | Oct 19, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Eugia Pharma | PAZOPANIB HYDROCHLORIDE | pazopanib hydrochloride | TABLET;ORAL | 219034-001 | Dec 4, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Novugen | PAZOPANIB HYDROCHLORIDE | pazopanib hydrochloride | TABLET;ORAL | 218231-001 | Apr 23, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
